أعرض في EDS

Long non-coding RNAs: From disease code to drug role

التفاصيل البيبلوغرافية
العنوان: Long non-coding RNAs: From disease code to drug role
المؤلفون: Li Zhaojun, Sen Zhang, Yuanyuan Chen, Xiaoguang Chen
المصدر: Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 2, Pp 340-354 (2021)
بيانات النشر: Elsevier BV, 2021.
سنة النشر: 2021
مصطلحات موضوعية: SNHG1, small nucleolar RNA host gene 1, BDNF-AS, brain-derived neurotrophic factor antisense, MHRT, myosin heavy chain associated RNA transcripts, Coding (therapy), Review, SncmtRNA, sense noncoding mitochondrial RNA, Disease, siRNAs, small interfering RNAs, TncRNA, trophoblast-derived noncoding RNA, PD, Parkinson's disease, pHLIP, pH-low insertion peptide, Delivery methods, Preclinical research, Clinical trials, MALAT1, metastasis associated lung adenocarcinoma transcript 1, 0302 clinical medicine, RISC, RNA-induced silencing complex, TTTY15, testis-specific transcript, Y-linked 15, UCA1, urothelial carcinoma-associated 1, Medicine, BCAR4, breast cancer anti-estrogen resistance 4, General Pharmacology, Toxicology and Pharmaceutics, LncRNAs, CASC9, cancer susceptibility candidate 9, THRIL, TNF and HNRNPL related immunoregulatory, media_common, ANRIL, antisense noncoding RNA gene at the INK4 locus, 0303 health sciences, NEAT1, nuclear enriched abundant transcript 1, NKILA, NF-kappaB interacting lncRNA, Small molecules, MM, multiple myeloma, HULC, highly upregulated in liver cancer, CHRF, cardiac hypertrophy related factor, MEG3, maternally expressed gene 3, TWIST1, twist family BHLH transcription factor 1, LIPCAR, long intergenic noncoding RNA predicting cardiac remodeling, CRISPR, clustered regularly interspaced short palindromic repeats, TUG1, taurine-upregulated gene 1, GAPDH, glyceraldehyde-3-phosphate dehydrogenase, 030220 oncology & carcinogenesis, HOTAIR, HOX transcript antisense intergenic RNA, Translational medicine, AD, Alzheimer's disease, mtlncRNA, mitochondrial long noncoding RNA, SALRNA1, senescence associated long non-coding RNA 1, Delivery, lincRNA-p21, long intergenic noncoding RNA p21, Drug, LNAs, locked nucleic acids, OIP5-AS1, opa-interacting protein 5 antisense transcript 1, DPF, diphenyl furan, media_common.quotation_subject, DACH1, dachshund homolog 1, Norad, non-coding RNA activated by DNA damage, ASO, antisense oligonucleotide, CDK, cyclin dependent kinase 1, Computational biology, 03 medical and health sciences, Genetic engineering, Gene therapy, DANCR, differentiation antagonizing non-protein coding RNA, PVT1, plasmacytoma variant translocation 1, ASncmtRNA, antisense noncoding mitochondrial RNA, GAS5, growth arrest specific 5, ENE, element for nuclear expression, NPs, nanoparticles, RGD, arginine-glycine-aspartic acid peptide, PEG, polyethylene glycol, 030304 developmental biology, PNAs, peptide nucleic acids, Targeted drug, business.industry, Erbb4-IR, Erb-B2 receptor tyrosine kinase 4-immunoreactivity, lcsh:RM1-950, ASncmtRNA, lncRNAs, long non-coding RNAs, HISLA, HIF-1α-stabilizing long noncoding RNA, sgRNA, single guide RNA, EBF3-AS, early B cell factor 3-antisense, UTF1, undifferentiated transcription factor 1, Clinical trial, FDA, U.S. Food and Drug Administration, lcsh:Therapeutics. Pharmacology, PTO, phosphorothioate, DKD, diabetic kidney disease, XIST, X-inactive specific transcript, business
الوصف: Enormous studies have corroborated that long non-coding RNAs (lncRNAs) extensively participate in crucial physiological processes such as metabolism and immunity, and are closely related to the occurrence and development of tumors, cardiovascular diseases, nervous system disorders, nephropathy, and other diseases. The application of lncRNAs as biomarkers or intervention targets can provide new insights into the diagnosis and treatment of diseases. This paper has focused on the emerging research into lncRNAs as pharmacological targets and has reviewed the transition of lncRNAs from the role of disease coding to acting as drug candidates, including the current status and progress in preclinical research. Cutting-edge strategies for lncRNA modulation have been summarized, including the sources of lncRNA-related drugs, such as genetic technology and small-molecule compounds, and related delivery methods. The current progress of clinical trials of lncRNA-targeting drugs is also discussed. This information will form a latest updated reference for research and development of lncRNA-based drugs.
Graphical abstract This review summarizes the current knowledge on pre- and clinical transformation of lncRNAs-based drugs, covering latest strategies to target pathogenic lncRNAs, indispensable delivery systems, arising clinical trials, future directions and challenges.Image 1
تدمد: 2211-3835
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1331163087be50317f3485f73580768Test
https://doi.org/10.1016/j.apsb.2020.10.001Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....a1331163087be50317f3485f73580768
قاعدة البيانات: OpenAIRE
الوصف
تدمد:22113835